Genetic Determinants of Clozapine-Induced Metabolic Side Effects.

ABSTRACT:

Objective

Atypical antipychotics are linked to a higher incidence of metabolic side effects, including weight gain, dyslipidemia, and diabetes. In this study, we examined the prevalence and potential genetic predictors of metabolic side effects in 60 adult patients on clozapine.

Method

Genetic variants of relevance to clozapine metabolism, clearance, and response were assessed through targeted genotyping of cytochrome P450 enzymes CYP1A2 and CYP2C19, the efflux transporter ABCB1, the serotonin receptor (HTR2C), leptin (LEP), and leptin receptor (LEPR). Clozapine levels and other potential confounders, including concurrent medications, were also included in the analysis.

Results

More than half of the patients were obese (51%), had metabolic syndrome (52.5%), and 30.5%

SUBMITTER: Vasudev K 

PROVIDER: S-EPMC5298525 | biostudies-literature | 2017 Feb

REPOSITORIES: biostudies-literature